Search results

Coagulation assays, such as the Activated Partial Thromboplastin Time (APTT) or for the assays of factors of the intrinsic coagulation pathway.

Coagulation assays, such as the activated partial thromboplastin time (aPTT) or for the assays of factors of the intrinsic coagulation pathway.

Quality control titrated and optimized for anti-IIa colorimetric assays (HEMOCLOT Thrombin Inhibitors: ref. CK002K/CK002L).

Quality control titrated and optimized for anti-IIa colorimetric assays (HEMOCLOT Thrombin Inhibitors: ref. CK002K/CK002L).

Quantitative measurement of dabigatran, and anti-thrombin activities in plasma (e.g. Dabigatran Plasma Calibrator (ref. 222801), Dabigatran Control Plasma (ref. 224701), Argatroban Plasma Calibrator (ref. SC030K), Argatroban Control Plasma (ref. SC035K)).

Quantitative measurement of dabigatran, and anti-thrombin activities in plasma (e.g. Dabigatran Plasma Calibrator (ref. 222801), Dabigatran Control Plasma (ref. 224701), Argatroban Plasma Calibrator (ref. SC030K), Argatroban Control Plasma (ref. SC035K)).

Calibration of a modified one-stage FVIII activity assay for determination of active emicizumab concentration from a clot time measurement performed on an automated coagulation analyzer.

Quality control of a modified one-stage FVIII activity assay for determination of active emicizumab concentration from a clot time measurement performed on an automated coagulation analyzer.

Measurement of fibrinogen in plasma. Detection of low fibrinogen concentrations. Detection of elevated fibrinogen concentrations (> 4g/L): In clinical situations associated with inflammation Risk factor for cardiovascular disease and thrombosis Hypofibrinogenemia, mainly associated with severe liver disease, and excessive consumption of fibrinogen (DIC, hyperfibrinolysis). Numerous variants of fibrinogen described, associated to asymptomatic cases, or to cases with bleeding and/or thrombosis.